Radiance Biopharma

Radiance Biopharma is revolutionizing cancer treatment with groundbreaking innovations in Antibody Drug Conjugates and Bispecific Antibody Drug Conjugates, leveraging cutting-edge technology to address critical unmet medical needs and transform patient outcomes.

https://radiancebio.com

2-10 employees

Growth Trajectory

Radiance Biopharma's growth is indicated by their collaboration with CSPC for clinical development in the US and other territories, as well as planned clinical trials for RB-201. They aim to expand their pipeline of next-generation ADCs and focus on innovative targets, conjugation methods, and bispecific ADC technology, reflecting a commitment to future development and market expansion.

Technical Challenges

Tech Stack

Antibody Drug Conjugate (ADC) technologyBispecific antibody technologyMonoclonal antibody technologyProprietary conjugation/linker technologiesTheranosticsImmunotherapies

Team Size

Key Risks

Competition from other companies in the ADC space, including Merck's ROR1 ADC.

Regulatory hurdles and the need for FDA approval for their ADC products.

Potential challenges in the clinical development and commercialization of their ADC pipeline.

Opportunities

Addressing high unmet medical needs in cancer treatment through innovative ADC therapies.

Leveraging novel targets, linkers, and conjugation methods to improve ADC technology and efficacy.

Expanding clinical development efforts in the US and other licensed territories, potentially through partnerships.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes